



NUCLEAR MEDICINE


5th
Edition

WORLD MARKET REPORT & DIRECTORY

EDITION 2018

Nuclear Medicine, Edition 2018

- The global market for nuclear medicine reached US\$ 4.8 billion in 2017, growing by 7% from 2016.
- The market is expected to reach between US\$ 14 and 26 billion in 2030.




Nuclear Medicine, Edition 2018

- Nuclear medicine remains a niche market representing less than 1% of the global pharmaceutical industry, but new opportunities lie ahead, especially in radiotherapeutics
 - Over five new radiotherapeutics with a blockbuster potential (annual sales potential \geq US\$ 1 billion) to reach the market before 2025
- Radiotherapeutics represented 13% of the global nuclear medicine market in 2017 and are expected to reach 60% by 2030.
- New radiotheranostics under development might lead to much stronger market figures than expected in coming years

Nuclear Medicine, Edition 2018

- Five companies controlled 67% of the world nuclear medicine market in 2017, the remaining 33% of the market is shared by 68 companies.




Nuclear Medicine, Edition 2018

- During 2017, over 100 radiopharmaceuticals were marketed around the World, but some were only available locally
- The top 10 radiopharmaceuticals accounted for over 20% of the world market
- ^{99m}Tc based radiopharmaceuticals accounted for over 50% of the world market (in US\$), radiotherapeutics accounted for 13%
- Innovative solutions and additional sources will also emerge to cover the need for ^{99}Mo
- ^{177}Lu became the radionuclide of choice for therapy and only with some exceptions for which ^{131}I is preferred almost all new radiotherapeutics are based on this radionuclide

Nuclear Medicine, Edition 2018

- Over 50 companies are currently developing one or more radiopharmaceuticals / radiotherapeutics from their own pipeline

*Radiotherapeutics
under development*




© MEDraysintell 2018

Nuclear Medicine, Edition 2018

- Nuclear Medicine World Market Report and Directory Edition 2018
 - A 1,200-page document
 - 420 products extensively described with over 150 radiopharmaceuticals under clinical development
 - 219 companies profiled
 - More than 500 direct web links with additional information
- This fifth edition will prove once again to be the best advising tool for the pharmaceutical and radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.

How to subscribe?



To request a detailed table of contents with some sample pages and to order, please send an e-mail with your contact details to Paul-Emmanuel GOETHALS at: peg@medraysintell.com

Price: EUR 8,000

**ORDER
Now!**

About MEDraysintell





More than 70 years of experience in

- Nuclear Medicine
- Particle therapy
- Brachytherapy

MEDraysintell provides strategic intelligence for the radiation healthcare to help clients understand

- Markets
- Competitive environment
- Potential for M&A
- Technology development

The most comprehensive set of reports & directories with over 2,200 pages of unrivaled intelligence, covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment



Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

Contact

- MEDraysintell reports and directories can be customized to specific areas or modalities
 - Sample pages and complete table of contents are available upon request
 - MEDraysintell also welcomes your requests for specific intelligence needs
-

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
peg@medraysintell.com
Phone: +32 491 080 968

Dr. Richard Zimmermann, PhD
Lalaye, France
rz@medraysintell.com
Phone: +33 6 82 80 06 00

www.medraysintell.com

Disclaimer

This MEDraysintell presentation and information contained herein, coming from the report “Nuclear Medicine World Market Report & Directory, Edition 2018” is believed to be accurate at the time of publication; it has been gathered in good faith from several public sources, but the authors are not in a position to guarantee its accuracy. The authors do not accept any responsibility for the content of this report/presentation. Information contained herein may be of a speculative nature and must be used with careful consideration. The authors assume no liability for any loss or damage – including but not limited to lost time, lost money, lost profits, lost customers – that may result from any use of the information or actions taken based on any analyses, projections, discussions, recommendations, or conclusions of any kind presented in this report/presentation.